Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 9, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Definitive Radiation Therapy for Older Adults With Localized Prostate Cancer.

Francis M Wright1, Dexiang Gao2, Christopher L Geiger3

  • 1Internal Medicine, University of Colorado School of Medicine, Aurora, USA.

Cureus
|June 8, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wide Temperature Zero Thermal Expansion in Al Matrix Composites with High Thermal Conductivity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Integrated drought monitoring and analysis: A novel framework based on multi-source remote sensing data and ensemble machine learning.

PloS one·2026
Same author

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.

Advances in radiation oncology·2026
Same author

Interfacial Energy Engineering via Fluorine Doping Suppresses Lithium Self-Permeation in Li<sub>3</sub>N Solid Electrolytes.

Nano letters·2026
Same author

Tunable exchange bias, magnetoelectric transport and negative thermal expansion in Mn<sub>3</sub>Ni<sub>1-<i>x</i></sub> Co <sub><i>x</i></sub> N.

iScience·2026
Same journal

Retraction: The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia.

Cureus·2026
Same journal

Patient-Reported Understanding of Emergency Department Discharge Instructions, Satisfaction, and Acceptability of a Future Telemedicine-Based Call-Back Program: Phase 1 Observational Pilot Study at a Tertiary Hospital in Dubai, United Arab Emirates.

Cureus·2026
Same journal

Correction: Methylprednisolone-Induced Delayed and Sustained Bradycardia in Multisystem Inflammatory Syndrome in Children.

Cureus·2026
Same journal

Rapid Interval Development of a Left Hepatic Artery Pseudoaneurysm During Acute Interstitial Edematous Pancreatitis.

Cureus·2026
Same journal

Recurrent Acute Pancreatitis Secondary to Untreated Hyperparathyroidism: A Case Report and Literature Review.

Cureus·2026
Same journal

A Prospective Case-Control Study of Helicobacter pylori and Systemic Inflammation in Colorectal Cancer Pathogenesis.

Cureus·2026
See all related articles

Definitive radiation therapy (RT) for prostate cancer in patients 80 years and older is well-tolerated and effective. This treatment approach offers a favorable risk/benefit ratio, supporting individualized care over age-based restrictions.

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Radiation Oncology

Background:

  • Individual health and life expectancy, not age, should guide prostate cancer management.
  • Limited data exists on treatment outcomes for older adults receiving curative-intent therapy.
  • This study focuses on radiation therapy (RT) outcomes in patients aged 80+.

Purpose of the Study:

  • To report treatment outcomes and tolerance of definitive RT for localized prostate cancer in patients aged 80 years and older.
  • To evaluate toxicity, symptom scores, and oncologic outcomes (biochemical recurrence, distant metastases, overall survival).
  • To inform clinical decision-making for this specific patient population.

Main Methods:

  • Retrospective study of 41 patients aged 80+ receiving RT for localized prostate cancer (2004-2022).
Keywords:
aua scorebiochemical recurrencedefinitive radiation therapygenitourinary complicationsgeriatric oncologygeriatricslocalized prostate cancermoderate hypofractionationpsa screeningradiation side effects

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

  • Data collected included baseline characteristics, toxicity (CTCAE), International Prostate Symptom Score (IPSS), biochemical recurrence (BR), distant metastases (DM), and overall survival (OS).
  • Statistical analysis performed using Graphpad Prism and R software.

    • Main Results:

    • No grade 4+ adverse events; low rates of grade 3 proctitis (2.4%) and grade 2 genitourinary AEs (acute 17.1%, late 12.2%).
    • Urinary symptoms improved post-RT (IPSS decreased from 12.1 to 8.2).
    • Four-year cumulative incidence of metastases was 6.7%; no statistically significant differences in BR, DM, or OS between intermediate and high/very high-risk groups.

    Conclusions:

    • Definitive RT is generally well-tolerated and effective in select patients aged 80 years and older with localized prostate cancer.
    • Findings suggest a favorable risk/benefit ratio for definitive RT in this cohort.
    • Treatment decisions should prioritize comprehensive assessment of individual health and life expectancy over chronological age.